Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.51
MACK's Cash to Debt is ranked lower than
87% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 56.57 vs. MACK: 0.51 )
Ranked among companies with meaningful Cash to Debt only.
MACK' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 2.45 Max: No Debt
Current: 0.51
Equity to Asset -1.13
MACK's Equity to Asset is ranked lower than
97% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. MACK: -1.13 )
Ranked among companies with meaningful Equity to Asset only.
MACK' s Equity to Asset Range Over the Past 10 Years
Min: -4.85  Med: -0.71 Max: 0.24
Current: -1.13
-4.85
0.24
F-Score: 3
Z-Score: -6.23
M-Score: -0.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -135.48
MACK's Operating margin (%) is ranked lower than
57% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.21 vs. MACK: -135.48 )
Ranked among companies with meaningful Operating margin (%) only.
MACK' s Operating margin (%) Range Over the Past 10 Years
Min: -2220.11  Med: -239.28 Max: -64.48
Current: -135.48
-2220.11
-64.48
Net-margin (%) -158.49
MACK's Net-margin (%) is ranked lower than
58% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. MACK: -158.49 )
Ranked among companies with meaningful Net-margin (%) only.
MACK' s Net-margin (%) Range Over the Past 10 Years
Min: -2284.59  Med: -239.15 Max: -81.06
Current: -158.49
-2284.59
-81.06
ROA (%) -99.45
MACK's ROA (%) is ranked lower than
88% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -26.89 vs. MACK: -99.45 )
Ranked among companies with meaningful ROA (%) only.
MACK' s ROA (%) Range Over the Past 10 Years
Min: -110.9  Med: -74.21 Max: -47.45
Current: -99.45
-110.9
-47.45
ROC (Joel Greenblatt) (%) -665.63
MACK's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. MACK: -665.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MACK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1458.87  Med: -949.42 Max: -468.88
Current: -665.63
-1458.87
-468.88
Revenue Growth (3Y)(%) -31.20
MACK's Revenue Growth (3Y)(%) is ranked lower than
77% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. MACK: -31.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MACK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -36.10 Max: -31.2
Current: -31.2
EBITDA Growth (3Y)(%) -55.10
MACK's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. MACK: -55.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MACK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -55.10 Max: -32.4
Current: -55.1
EPS Growth (3Y)(%) -51.50
MACK's EPS Growth (3Y)(%) is ranked lower than
92% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. MACK: -51.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MACK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -51.50 Max: -33.8
Current: -51.5
» MACK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MACK Guru Trades in Q2 2015

Jim Simons 17,113 sh (New)
Murray Stahl 19,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q3 2015

MACK Guru Trades in Q3 2015

Murray Stahl 25,000 sh (+31.58%)
Jim Simons Sold Out
» More
Q4 2015

MACK Guru Trades in Q4 2015

Murray Stahl 25,000 sh (unchged)
» More
Q1 2016

MACK Guru Trades in Q1 2016

Paul Tudor Jones 17,800 sh (New)
Jim Simons 636,613 sh (New)
Murray Stahl 25,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MACK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:BSLN, NAS:MGNX, ROCO:4105, XKRX:003000, SZSE:300049, NAS:RGEN » details
Traded in other countries:MP6.Germany,
Merrimack Pharmaceuticals Inc is engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer.

Merrimack Pharmaceuticals Inc was incorporated in the Commonwealth of Massachusetts in 1993 and reincorporated under the laws of the State of Delaware in October 2010. The Company is a biopharmaceutical company engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer. Its core approach to systems biology is to apply multidisciplinary and multi technology capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks, that allow to engineer treatments that are directed at the mechanisms of disease. The Company currently has six targeted therapeutic oncology candidates in clinical development, are either monoclonal antibodies or monoclonal antibody-derived molecules that are designed to block oncogenic signaling pathways, such as MM-121, MM-111, MM-151 and MM-141, or nanotherapeutics, such as MM-398 and MM-302, that are designed to preferentially deliver cytotoxic therapies to the tumor tissue. MM-398 is a novel, stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors. Its Phase 3 clinical trial of MM-398 is focused on pancreatic cancer, and used in a number of other solid tumor indications, including colorectal cancer, lung cancer, breast cancer, glioma and pediatric solid tumors. Its MM-121 is a fully human monoclonal antibody that targets the ErbB3 cell surface receptor. MM-121 is designed to inhibit cancer growth directly, restore a tumor's sensitivity to drugs to which it has become resistant, and delay the development of resistance by a tumor to other agents. Its MM-111 is a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 (HER2) cell surface receptor. MM-111 is designed to anchor to both receptors, ErbB2 (HER2) and HER3, on the cell surface and block heregulin's ability to transmit tumor growth signals, thus inhibiting the tumor cell's ability to thrive. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. It is designed to target and bind to cancer cells that overexpress ErbB2 (HER2) and thereby release doxorubicin at the site of the tumor, while minimizing uptake into normal cells, including those of the heart. MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of EGFR (ErbB1). MM-151 is in its Phase 1 clinical trial for patients with refractory solid tumors. Its MM-141 is a fully human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth

Ratios

vs
industry
vs
history
P/S 7.40
MACK's P/S is ranked higher than
64% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. MACK: 7.40 )
Ranked among companies with meaningful P/S only.
MACK' s P/S Range Over the Past 10 Years
Min: 1.78  Med: 9.59 Max: 16.67
Current: 7.4
1.78
16.67
Current Ratio 1.65
MACK's Current Ratio is ranked lower than
80% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. MACK: 1.65 )
Ranked among companies with meaningful Current Ratio only.
MACK' s Current Ratio Range Over the Past 10 Years
Min: 0.69  Med: 2.08 Max: 4.51
Current: 1.65
0.69
4.51
Quick Ratio 1.57
MACK's Quick Ratio is ranked lower than
77% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. MACK: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
MACK' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 2.06 Max: 4.51
Current: 1.57
0.69
4.51
Days Inventory 1.00
MACK's Days Inventory is ranked higher than
97% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. MACK: 1.00 )
Ranked among companies with meaningful Days Inventory only.
MACK' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 1
Days Sales Outstanding 59.64
MACK's Days Sales Outstanding is ranked higher than
53% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. MACK: 59.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
MACK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.77  Med: 68.23 Max: 300.77
Current: 59.64
11.77
300.77
Days Payable 5.00
MACK's Days Payable is ranked lower than
88% of the 442 Companies
in the Global Biotechnology industry.

( Industry Median: 60.55 vs. MACK: 5.00 )
Ranked among companies with meaningful Days Payable only.
MACK' s Days Payable Range Over the Past 10 Years
Min: 0.82  Med: 12.96 Max: 22
Current: 5
0.82
22

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.77
MACK's Price/Median PS Value is ranked higher than
66% of the 679 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. MACK: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
MACK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.19  Med: 1.06 Max: 1.4
Current: 0.77
0.19
1.4
Earnings Yield (Greenblatt) (%) -13.80
MACK's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: -9.20 vs. MACK: -13.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MACK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -17.16  Med: 0.00 Max: 0
Current: -13.8
-17.16
0

More Statistics

Revenue (TTM) (Mil) $95.70
EPS (TTM) $ -1.33
Beta1.35
Short Percentage of Float22.68%
52-Week Range $5.02 - 13.00
Shares Outstanding (Mil)127.73

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 166 245 342
EPS ($) -0.71 -0.19 0.22
EPS without NRI ($) -0.71 -0.19 0.22
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:MACK

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Starbucks Corp, KD Supply Holdings Inc, Capital One Financial Corp, Merr Dec 14 2014 

More From Other Websites
Coverage initiated on Merrimack Pharma by Robert W. Baird May 27 2016
Merrimack/Baxalta Start Study on Colorectal Cancer Drug May 20 2016
ETF’s with exposure to Merrimack Pharmaceuticals, Inc. : May 19, 2016 May 19 2016
Targeting cancer May 19 2016
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the... May 19 2016
Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients... May 19 2016
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the... May 19 2016
Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical... May 18 2016
Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical... May 18 2016
Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the... May 17 2016
Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the... May 17 2016
MERRIMACK PHARMACEUTICALS INC Financials May 07 2016
Merrimack Pharmaceuticals, Inc. :MACK-US: Earnings Analysis: Q1, 2016 By the Numbers May 04 2016
Merrimack (MACK) Posts Narrower-than-Expected Loss in Q1 May 03 2016
​Sales of Merrimack’s new pancreatic cancer drug top $11M in Q1 May 03 2016
Edited Transcript of MACK earnings conference call or presentation 2-May-16 8:30pm GMT May 02 2016
Merrimack Reports First Quarter 2016 Financial Results May 02 2016
Merrimack reports 1Q loss May 02 2016
Merrimack reports 1Q loss May 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)